10-Q: GE HealthCare Q1 2026 Earnings: Revenue Up, Profit Down

GE HealthCare reported a 7.4% increase in total revenues for Q1 2026, reaching $5.13 billion, but net income attributable to GE HealthCare decreased by 31.0% to $389 million.

Summary

• GE HealthCare reported total revenues of $5.131 billion for the first quarter of 2026, a 7.4% increase compared to the same period in 2025.
• Net income attributable to GE HealthCare decreased by 31.0% to $389 million, or $0.85 per diluted share, down from $564 million, or $1.23 per diluted share, in Q1 2025.
• The company's Imaging segment saw a 7.4% revenue increase, while Pharmaceutical Diagnostics (PDx) revenue grew by 21.7%.
• Patient Care Solutions (PCS) segment revenue declined by 6.5%.
• Operating income decreased by 18.2% to $515 million.
• The company completed the acquisition of Intelerad for approximately $2.3 billion in cash.
• Tariffs materially impacted operating income by approximately $90 million and cash flows by approximately $110 million for the quarter.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant decrease in net income and operating income, despite revenue growth, largely driven by cost inflation and tariffs.

Positives

• Total revenues increased by 7.4% to $5.131 billion, driven by growth in PDx, Imaging, and AVS segments, as well as favorable foreign currency impacts.
• Pharmaceutical Diagnostics (PDx) segment revenue showed strong growth of 21.7%, with organic revenue up 9.7% due to volume, price, and new product introductions.
• Advanced Visualization Solutions (AVS) segment revenue increased by 8.2%, with organic revenue up 4.4%.
• Imaging segment revenue grew by 7.4%, with organic revenue up 3.8%.
• The company completed the acquisition of Intelerad, a medical imaging software and digital enterprise workflow solutions company, for approximately $2.3 billion.
• Free cash flow increased by 13.3% to $112 million.

Negatives

• Net income attributable to GE HealthCare decreased significantly by 31.0% to $389 million.
• Operating income decreased by 18.2% to $515 million.
• Patient Care Solutions (PCS) segment revenue decreased by 6.5% due to timing of installations.
• Gross profit decreased by $36 million, with cost of products and cost of services increasing as a percentage of sales, largely due to cost inflation and incremental tariffs.
• Selling, general, and administrative expenses increased by $77 million, primarily due to foreign currency movements and expenses related to recent acquisitions.
• The company experienced a $90 million negative impact on operating income and a $110 million impact on cash flows due to tariffs.

Risks

• Tariffs materially impacted operating income by approximately $90 million and cash flows by approximately $110 million for the three months ended March 31, 2026, and the company expects continued material impact if tariffs remain at current levels.
• Additional tariffs or other trade restrictions by the U.S. or other countries could further materially impact results.
• Mitigation actions are not expected to fully offset the additional costs or other negative impacts from tariffs.
• Global geopolitical instability, including the conflict in the Middle East, could adversely impact operations, supply chains, and logistics, potentially resulting in increased costs and delivery delays.
• Sustained cost inflation or constrained availability of critical components could negatively impact the ability to produce and deliver products in a timely manner.
• Increased competition from local companies and volume-based procurement policies in China have impacted and may continue to impact orders and revenues.
• The Russia and Ukraine conflict continues to be monitored for financial impact, cybersecurity risks, sanctions, and employee base implications.
• Potential product liability claims or litigation, arbitration, or similar proceedings are a risk.

Future Outlook

The company expects to continue to see a material impact from tariffs if they remain at current levels. While mitigation actions are being taken, they are not expected to fully offset the additional costs or negative impacts. The company continues to monitor global markets for changes in customer behavior, government spending, and inflation, which could adversely impact the business. Investments in China are expected to benefit the business long-term, but competition and procurement policies remain a concern. The company believes its current cash balance, operating cash flow, and credit facilities will be sufficient to meet its needs for at least the next 12 months.

Management Comments

• "While the situation continues to be fluid, tariffs materially impacted our Operating income by approximately $90 million and cash flows by approximately $110 million for the three months ended March 31, 2026, primarily the bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers."
• "Should the tariffs continue at current levels, we expect to continue to see a material impact to our financial results."
• "We continue to monitor the global markets in which we operate for changes in customer behavior, changes in government spending and reimbursement, and indirect impacts from the tariffs."
• "We believe the focus of government policy in China is on expanding access to healthcare. In addition, our investments to address clinical needs, localization, and commercial infrastructure should benefit our business in China in the long term."
• "We continue to monitor developments in the China market, including increased competition from local companies and the prevalence of volume based procurement policies, both of which have impacted our orders and revenues and may continue to do so."
• "We believe that our performance and future success depend on a number of factors that present significant opportunities for us but also pose risks and challenges."

Industry Context

StockSavvy.ai notes that GE HealthCare's Q1 2026 results reflect ongoing challenges in the global healthcare technology market, including the impact of tariffs and geopolitical instability, alongside strategic growth initiatives like acquisitions. The company's performance in key segments like PDx and Imaging shows resilience, while other segments face headwinds. The reported results align with broader industry trends of increased costs and supply chain pressures, balanced by innovation and market expansion efforts.

Comparison to Industry Standards

• GE HealthCare's revenue growth of 7.4% in Q1 2026 is a solid performance in a competitive healthcare technology market, though it lags behind some specialized diagnostic or AI-focused companies that might report higher percentage growth from smaller bases.
• The decline in net income and operating income, attributed partly to tariffs and cost inflation, is a concern that may be shared by other global manufacturers facing similar macroeconomic pressures.
• The acquisition of Intelerad for $2.3 billion demonstrates a strategic move to bolster its AI and workflow solutions, a trend seen across the industry as companies seek to integrate advanced digital capabilities.
• The company's focus on segments like Pharmaceutical Diagnostics (PDx) and Imaging, which showed strong growth, aligns with continued demand for diagnostic tools and advanced imaging technologies globally.

Legal Proceedings

• A complaint was filed in the U.S. District Court for the District of Columbia alleging that GE HealthCare and certain affiliates violated the U.S. Anti-Terrorism Act by providing funding for an Iraqi terrorist organization through their sales practices with the Iraqi Ministry of Health. The case has been remanded for further proceedings after a Supreme Court decision and subsequent Court of Appeals rulings.
• The company is involved in various other arbitrations, class actions, commercial, intellectual property, and product liability litigation, and government investigations, for which it is often difficult to estimate potential losses.

Related Party Transactions

• The company has an ongoing IRS audit for the years 2016-2020, in which GE HealthCare is included. Any tax obligations would be allocated between GE HealthCare and GE according to the Tax Matters Agreement. A final resolution is not likely within the next 12 months, and an unfavorable resolution could result in additional material indemnification obligations to GE.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and earnings per share, despite revenue growth.
• Employees may be impacted by ongoing restructuring activities, which include workforce reductions.
• Customers may experience potential impacts from supply chain disruptions and increased costs due to tariffs and geopolitical instability.
• Suppliers may be affected by the company's participation in voluntary supply chain finance programs.

Next Steps

• The company will continue to monitor the impact of tariffs and global macroeconomic conditions on its financial results.
• GE HealthCare will integrate Intelerad into its Imaging segment.
• Beginning with the Form 10-Q filing for the period ending June 30, 2026, historical segment financial information will be recast to conform to a new reportable segment structure combining Imaging and AVS into Advanced Imaging Solutions (AIS).
• The company expects to incur additional restructuring expenses of approximately $25 million over the next 12 months.

Key Dates

Recommendation

While GE HealthCare demonstrated revenue growth and completed a significant acquisition, the substantial decrease in net income and operating income due to cost inflation and tariffs, coupled with ongoing geopolitical risks, warrants a cautious approach. The company's ability to navigate these headwinds and realize synergies from its acquisitions will be key. Therefore, a 'hold' recommendation is appropriate pending further clarity on cost management and the impact of external factors.

Keywords

GE HealthCare, 10-Q, Quarterly Report, Financial Results, Revenue, Net Income, Operating Income, Acquisition, Intelerad, Tariffs, Healthcare Technology, Medical Devices